These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 32817336)

  • 41. Type III CRISPR-Cas System: Introduction And Its Application for Genetic Manipulations.
    Liu T; Pan S; Li Y; Peng N; She Q
    Curr Issues Mol Biol; 2018; 26():1-14. PubMed ID: 28879852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CRISPR-Cas: Complex Functional Networks and Multiple Roles beyond Adaptive Immunity.
    Faure G; Makarova KS; Koonin EV
    J Mol Biol; 2019 Jan; 431(1):3-20. PubMed ID: 30193985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical characterization of RNA-guided ribonuclease activities for CRISPR-Cas9 systems.
    Gramelspacher MJ; Hou Z; Zhang Y
    Methods; 2020 Feb; 172():32-41. PubMed ID: 31228550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diverse virus-encoded CRISPR-Cas systems include streamlined genome editors.
    Al-Shayeb B; Skopintsev P; Soczek KM; Stahl EC; Li Z; Groover E; Smock D; Eggers AR; Pausch P; Cress BF; Huang CJ; Staskawicz B; Savage DF; Jacobsen SE; Banfield JF; Doudna JA
    Cell; 2022 Nov; 185(24):4574-4586.e16. PubMed ID: 36423580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies.
    Newsom S; Parameshwaran HP; Martin L; Rajan R
    Front Cell Infect Microbiol; 2020; 10():619763. PubMed ID: 33585286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitory mechanism of CRISPR-Cas9 by AcrIIC4.
    Li X; Liao F; Gao J; Song G; Zhang C; Ji N; Wang X; Wen J; He J; Wei Y; Zhang H; Li Z; Yu G; Yin H
    Nucleic Acids Res; 2023 Sep; 51(17):9442-9451. PubMed ID: 37587688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRISPR-CasΦ from huge phages is a hypercompact genome editor.
    Pausch P; Al-Shayeb B; Bisom-Rapp E; Tsuchida CA; Li Z; Cress BF; Knott GJ; Jacobsen SE; Banfield JF; Doudna JA
    Science; 2020 Jul; 369(6501):333-337. PubMed ID: 32675376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.
    Grüschow S; Athukoralage JS; Graham S; Hoogeboom T; White MF
    Nucleic Acids Res; 2019 Sep; 47(17):9259-9270. PubMed ID: 31392987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA and RNA interference mechanisms by CRISPR-Cas surveillance complexes.
    Plagens A; Richter H; Charpentier E; Randau L
    FEMS Microbiol Rev; 2015 May; 39(3):442-63. PubMed ID: 25934119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA
    Brown S; Gauvin CC; Charbonneau AA; Burman N; Lawrence CM
    J Biol Chem; 2020 Oct; 295(44):14963-14972. PubMed ID: 32826317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Target preference of Type III-A CRISPR-Cas complexes at the transcription bubble.
    Liu TY; Liu JJ; Aditham AJ; Nogales E; Doudna JA
    Nat Commun; 2019 Jul; 10(1):3001. PubMed ID: 31278272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
    Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
    Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Substrate generation for endonucleases of CRISPR/cas systems.
    Zoephel J; Dwarakanath S; Richter H; Plagens A; Randau L
    J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.
    Zetsche B; Gootenberg JS; Abudayyeh OO; Slaymaker IM; Makarova KS; Essletzbichler P; Volz SE; Joung J; van der Oost J; Regev A; Koonin EV; Zhang F
    Cell; 2015 Oct; 163(3):759-71. PubMed ID: 26422227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of advances in CRISPR/deadCas9 technology and its applications in human diseases.
    Kanafi MM; Tavallaei M
    Gene; 2022 Jul; 830():146518. PubMed ID: 35447246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells.
    Bigelyte G; Young JK; Karvelis T; Budre K; Zedaveinyte R; Djukanovic V; Van Ginkel E; Paulraj S; Gasior S; Jones S; Feigenbutz L; Clair GS; Barone P; Bohn J; Acharya A; Zastrow-Hayes G; Henkel-Heinecke S; Silanskas A; Seidel R; Siksnys V
    Nat Commun; 2021 Oct; 12(1):6191. PubMed ID: 34702830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
    Basila M; Kelley ML; Smith AVB
    PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.